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Abstract 
Background: Acute lymphoblastic leukemia (ALL) is one of the major lymphoid malignancies and the most 
common hematologic malignancy in children. ALL is characterized by the presence of malignant lymphoblasts in 
the blood so that immature lymphocytes cannot become mature and thus do not have an adult cell function. Although 
it is not unusual in adults, it usually affects children. Most children with this disease are recovered from therapeutic 
protocols. But the relapse is common after recovery or during the treatment. Various factors are supposed to 
contribute to the relapse of the disease. One of these factors that is likely to be effective in the recurrence of ALL is 
the FAIM3 protein (an FCuR), or the Fas inhibitory molecule-3 (FAIM3). The aim of this study was to investigate 
FAIM3 (TOSO) as a new prognostic factor in ALL. Materials and methods: In this study, 19 patients with newly 
diagnosed and 17 patients with relapsed ALL were included.  FAIM3 gene expression was measured with the qRT-
PCR method. Results:  The expression level of FAIM3 in relapsed patients was 5.44 folds higher than newly 
diagnosed ALL patients.  Conclusion: Prognosis of ALL is usually well-proven in children and can be cured. 
However, recurrence of the disease is common. At the molecular level, there are several factors that are referred to as 
the "factor involved in the relapse" of the disease. These factors increase the survival of the leukemic cells. 
According to the results of the present study, gene expression level of FAIM3 as an anti-apoptotic factor has 
increased in relapsed ALL lymphoblasts, compared with new diagnosed patients. Therefore, FAIM3 can be 
considered as a contributing factor in the relapse of the disease. 
Keywords: ALL, FAIM3, relapse, FCuR, Toso. 
 
*Corresponding Author: Mohammad Reza Rezvany; Email: : mohrezrez@yahoo.com, rezvani.mr@iums.ac.ir  
Please cite this article as: Valikhani M, Faranoush M, Namjoo S, Rezvany M.R. Comparison of FAIM3 gene expression between new 





Acute lymphoblastic leukemia is one of the 
most common types of leukemia. This type of 
leukemia affects the immature lymphatic cells that 
make up lymphoid tissues and has an acute 
process[1]. 
           In abnormal bone marrow leukemia, 
it produces a large number of blood cells. These cells 
differ in normal and do not function properly[2]. On 
the other hand, leukemia cells also affect the 
production of other types of blood cells made by the 
bone marrow, including red blood cells that transfer 
oxygen to the tissues of the body, and platelets that 
prevent blood clots. Therefore, in leukemia, the 
immune deficiency, Anemia and coagulation disorders 
are common[3, 4]. 
           Symptoms include tiredness, weakness, 
fading, bleeding or bruising, enlargement of the lymph 
nodes, spleen testis etc. or, in some cases, bone 
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pain[5]. Signs and symptoms of leukemia are often 
associated with infiltration of the leukemic cells in 
the normal tissue and ultimately cause bone marrow 
deficiency (anemia, neutropenia, and 
thrombocytopenia), or infiltration into specific 
tissues (lymph nodes, liver, spleen, brain, bone, skin, 
gums and testicles)[6]. Clinical examination often 
indicates lymphadenopathy and hepatosplenomegaly, 
and the symptoms of central nervous system 
involvement. The latter is rare at the time of 
diagnosis of acute lymphoblastic leukemia[4]. The 
testicles are the most common site of extra-bone 
involvement for ALL; the painless enlargement of 
one or both testicles may be seen [4, 7, 8]. 
           ALL treatment usually starts with 
chemotherapy, which in most cases causes a 
remission of the disease. After the initial remission, 
according to existing protocols, chemotherapy 
usually lasts more than a year to achieve the results 
of the flow-cytometry of the minimal residual disease 
(MRD) to the desired level[9, 10]. 
           The disease has an acute process and 
it has a desire prognosis in children. So that most 
children with this disease will improve through their 
treatment protocols[11, 12]. But the relapse is 
common after recovery or during treatment. Various 
factors have contributed to the relapse of the disease, 
and various studies have examined various factors in 
this regard. These factors usually play a role in the 
pathways for DNA repair, cell cycle regulation and 
apoptosis. These factors increase the survival of 
leukemia cells during recurrence[13, 14]. Among the 
studied genes in patients with leukemia  FAIM3 or 
FcμR gene or the Fas inhibitor molecule 3 (Fas 
inhibitory molecule3 or FAIM3), is more commonly 
studied in patients with chronic lymphocytic 
leukemia (CLL) as an anti-apoptotic factor[15, 16]. 
           This protein belongs to the membrane 
type I protein which has an immunoglobin-like 
domain and contains 390 amino acids (17 amino 
acids of the signal peptide and 234 amino acids in the 
extracellular region and 21 amino acids in the 
membrane and 118 amino acids in the cytoplasmic 
tail). Studies have shown that one-third of its 
molecular weight consists of carbohydrates and sialic 
acid [17-19].  FAIM3 is a single copied gene located 
on the chromosome 1q32.2 and in the vicinity of two 
other genes coding for IgM receptors. This gene 
contains 17.6 kb nucleotide and 8 exons. It has been 
shown that  FAIM3 is a Fas-dependent inhibitor of 
apoptosis[20]. However, recent studies have shown 
that this index does not directly inhibit FAS-dependent 
apoptosis. But only when an anti-FAS Ab of IgM 
isotype is used, it exhibits an inhibitory effect, and 
when anti-FAS Ab is from IgG it doesn't[18]. 
         FAIM3 gene expression in acute 
lymphoblastic leukemia appears to be involved in the 
relapse of the disease. One of the studies in this field 
that attempts to compare the expression of FAIM3 
expression between newly affected ALL and relapsed 
ALL is done by STAAL.  
          STAAL et al., In a comparative study 
between newly affected ALL and relapsed ALL, has 
demonstrated that six genes, including the  FAIM3 
gene, is up regulated in the relapse of the disease[21]. 
Also considering the role of this molecule in 
apoptosis, it is likely that it becomes the target 
molecules in the treatment process. Considering the 
fact that in Iran, the relationship between this gene and 
recurrence of disease in ALL patients has not been 




Patients. 19 patients with ALL that are newly 
affected and 17 patients with relapsed ALL was 
included in this study (Table1). After informed 
consent was given peripheral blood samples was 
obtained from 36 patients fulfilling diagnostic criteria 
for ALL. Total RNA was extracted from lymphocytes 
using Tripure isolation reagent (Roche, Basel, 
Switzerland), based on the manufacture’s instruction. 
One microgram RNA was used to invitro transcribed 
to cDNA by Revert Aid First strand cDNA synthesis 
kit (pars tous, cat. no.A101161). CDNA from patients 
with new ALL and relapsed ALL patients were 
evaluated using quantitative real-time PCR (qRT-
PCR) method to determine the presence of FAIM3 
mRNA. The results of the qRT-PCR test were checked 
on electrophoresis gel to ensure the presence of a 
specific FAIM3 bond. cDNA was made from RNAs 
through the recommended protocol of underlying 
cDNA synthesis kit. To confirm the synthesized 
cDNA, the housekeeping gene was used during the 
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real-time PCR. The gene used in this study was 
GAPDH. It is recommended to use conventional 
PCR and PCR product electrophoresis to confirm the 
cDNA, but in this study, to reduce the cost and 
timing, cDNA confirmation was done by GAPDH 
graph analyzing of real-time PCR. 
 
Quantitative real-time PCR. All samples 
were subjected to qRT-PCR in a duplicate manner. 
Primers were designed by using the Clone Manager 
software and were checked on the site http: // www. 
ncbi nlm.nih. gov / blast. The sequence is shown in 
the table below (Table2). The Forward and Reverse 
primers of the FAIM3 gene and GAPDH were each 
mixed separately before work by an equal amount. 
The materials were mixed into the nuclease free 
microtubes on ice. First, DEPC treated water, then 
Master Mixer, Primer and finally cDNA was added.  
The PCR protocol was run according   to following 
circumstances (Table3).  
 
PCR product electrophoresis. The PCR 
products were subjected to electrophoresis. A 1% TAE 
buffer was loaded on the gel of electrophoresis cast. 
Then samples were loaded on the gel and 80 voltage 
flow of electricity was applied for 1.5 to 2 hours. In 
one of the special well of gel the ladder was loaded. 




Melting curve (Figure1) and Amplification 
curve (Figure2) of the samples are given. 
The result of the real-time PCR reaction was 
taken on an agarose gel, as shown in Figure 3 and 
Figure 4. The FAIM3 gene expression rate was 
calculated using the following formula through using 
REST 2009 software. This software also calculates P 
value. Ex. Fold =2-ΔΔCt. 
Ex. Fold = expression Fold; ΔΔCt = ΔCt 
Relapsed –ΔCt New case. 
Table 1. Patient Demographic Information, M= Male, 
F=Female, N=New case, R=Relapse 
No. Gender Clinical Stage 
1 M N 
2 M N 
3 M N 
4 F N 
5 F N 
6 M N 
7 F N 
8 M N 
9 F N 
10 F N 
11 M N 
12 M N 
13 F N 
14 M N 
15 M N 
16 M N 
17 F N 
18 F N 
19 F N 
20 M R 
21 M R 
22 M R 
23 M R 
24 F R 
25 M R 
26 F R 
27 F R 
28 F R 
29 F R 
30 M R 
31 M R 
32 M R 
33 M R 
34 F R 
35 F R 
36 M R 
 
Table 2. Primers 





Length 19 20 
Tm(˚C) 57.18  53.72 





Length 23 20 
 





Temperature (oC) Phase 
1 290 95 
                 
Denaturation 
38 
15 95 Denaturation 
PCR 60 64 Annealing 
30 72 Extension 
1 1 97          Melting 
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 The analysis of real-time PCR data by this 
software showed that the expression of FAIM3 
expression in relapsed ALL patients was 5.44 fold 
higher of that of newly diagnosed ALL, (Figure5), 






          Studies that try to determine the role of 
FAIM3 have different implications for this protein. 
Sang and Jacob studies have shown that FAIM3-
expressing cells (Jurkat) are resistant to Fas-dependent 
apoptosis [22]. On the other hand, FAIM3 play a role 
in the internalization and transfer of IgM to lysosomal 
cells in CLL [23].  FAIM3 also plays an important role 
in resistance to bacterial infections since in a study it 
has been demonstrated that FAIM3 negative mice are 
susceptible to Listeria monocytogenes infection and 
death [24]. FAIM3 is also involved in the 
differentiation and maturation of inflammatory 
dendritic cells (iDC) and viral infection control [25]. 
          Regarding the presence of FAIM3 in 
the other white blood cells, in 2012, Lang et al studied 
the role of FAIM3 in granulocyte, monocyte and 
macrophage. Obtained results showed that FAIM3 is 
expressed in the granulocytes and monocytes and state 
that FAIM3 plays a role in granulocytic phagocytosis 
and the production of inflammatory cytokines such as 
IL-6 and TNF [26].  FAIM3 negative mice were not 
able to produce cytokine and died due to Listeria 
monocytogenes infection, highlighting antibacterial 
role of FAIM3 [24]. Unlike Lang et al study, Honio 
and colleagues, found that FAIM3 cell distribution is 
exclusively restricted to B, and NK cells, and its role 
in IgM hemostasis is further should be considered for 
the survival of B lymphocytes and humoral immune 
responses [27]. In a recent study, Lang et al have 
described that temperature and stress influence 
granulocytes by alteration of the FAIM3 expression. 
Also, the antibody affinity which is used in the flow 
 
Figure 1. Melting curve of both GAPDH and FAIM3 genes 
 
 
Figure 2. Amplification curve of both GAPDH and FAIM3 genes, 




Figure 3. Electrophoresis of real-time PCR products of FAIM3. 
Numbers of 1, 2 and 3 correspond to new cases samples. Numbers of 




Figure 4. Electrophoresis of real-time PCR products of GAPDH. 
Numbers of 1, 2 and 3 correspond to new cases samples. Numbers of 




Figure 5. Comparison of  FAIM3 gene expression between new 
cases of ALL and relapsed ALL ( fold change  ±SD). 
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cytometry technique, the granulocyte enrichment 
method and the staining protocols, are the effective 
factors in the diagnosis and evaluation of  FAIM3 
and lead to variation in the results [26].   
            Another category of studies has 
examined how FAIM3 up regulation or down 
regulation in various cell types or diseases. 
Expression of mRNA of FAIM3 gene in recent 
studies has been studied in CLL patients. In a study 
by Pallasch et al. patients with CLL showed that the 
expression of FAIM3 gene was 6.8 fold higher 
healthy individuals [16]. Marginal zone lymphoma, 
Hodgkin's lymphoma, and T cell lymphoma have 
also been investigated in terms of FAIM3 expression, 
and in these cases, no increase in expression has been 
recorded [16]. In the case of splenic marginal zone 
lymphoma (SMZL), Elena Ruiz-Ballesteros and 
colleagues showed that FAIM3 gene expression 
increases by 2.72 fold [28].  On the other hand, 
Richter et al have exhibited that siRNA-mediated 
FAIM3 gene repression can increase the sensitivity 
of IL-2 activated T-lymphocytes to FAS-dependent 
apoptosis [29]. Another study have demonstrated that 
activation of TLRs is a factor in reducing the 
expression of FAIM3 at both protein and mRNA 
levels [23]. The expression of FAIM3 in ALL has not 
been widely evaluated so that STAAL et al have 
investigated the role of five other genes on relapse. 
This study suggests that FAIM3 is up regulated in 
relapsed ALL patients compared with new cases of 
ALL. It has been shown by others FAIM3 have an 
anti-apoptotic role that contributes to the survival of 




          Many factors contribute to the 
pathways of DNA repair, cell cycle regulation, and 
apoptosis. These factors increase the survival of the 
leukemic cell. According to the results of this study, 
FAIM3 as an anti-apoptotic factor may have a role in 
relapse of ALL. Therefore, FAIM3 can be considered 
as a contributing factor in ALL. 
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